Cabazitaxel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals
Alternative Names: Cabazitaxel lipid suspensionLatest Information Update: 28 May 2022
At a glance
- Originator Intas Pharmaceuticals; Jina Pharmaceuticals
- Class Amines; Antineoplastics; Benzene derivatives; Esters; Small molecules; Taxanes
- Mechanism of Action Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in India (IV, Suspension)
- 12 May 2020 Phase-I development is ongoing for Cancer (Second-line therapy or greater, Late-stage disease) in India (IV, Suspension) (Jina Pharmaceuticals pipeline, May 2020)
- 28 Aug 2018 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in India (IV, Suspension)